Drugs / Apigenin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06889584 | Feb → Dec 2025 | — | University of South Carolina | Completed | No outcome recorded |
| — | NCT05696665 | Jul 2022 → Jul 2023 | Parkinson disease, neurodegenerative disease | Jinnah Postgraduate Medical Centre | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | apigenin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06889584 ↗ |
| Known as | AGN | “Apigenin (AGN), a non-mutagenic flavone found in fruits and vegetables, exhibits a variety of biological effects including anti-apoptotic, anti-inflammatory, and free radical...” PMID 28389404 ↗ Apr 2017 |
| Action | Inhibit | “AGN treatment downregulated α-synuclein aggregation and upregulated the TH protein expression” PMID 28389404 ↗ Apr 2017 |
| Modality | Small molecule | “Apigenin (AGN), a non-mutagenic flavone found in fruits and vegetables” PMID 28389404 ↗ Apr 2017 |